Filing Flows › Co-Diagnostics (CODX) › Q2 2026
Co-Diagnostics (CODX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Co-Diagnostics (CODX) reported revenue of $166K for the second quarter 2026 (Q2 2026), +2% from a year earlier and +14% from the quarter before.
Co-Diagnostics, Q2 2026: revenue $166K (+2% year over year), net loss $6.3M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $166K | +14% | +2% |
| Operating profit | −$6.2M | — | — |
| Net earnings | −$6.3M | — | — |
| Operating cash flow | −$7.2M | — | — |
What changed
Revenue was $166K in Q2 2026, up 2% year over year and up 14% from the previous quarter.
Gross margin was 72.7%, down 7.6 points from Q2 2025. Operating costs exceeded revenue by $6.2M, an operating margin of -3732.5%. Operating expenses fell 23% while revenue rose 2%. The quarter ended with a net loss of $6.3M, narrower than the previous quarter's $9.1M loss.
Operating cash flow was −$7.2M. Non-cash charges added back $202K of depreciation and amortization and $214K of share-based compensation. Working capital and other items used $1.3M. Capital expenditures of $18K exceeded it, leaving free cash flow of −$7.2M.
Questions
What was Co-Diagnostics' revenue in the second quarter 2026?
Co-Diagnostics (CODX) reported revenue of $166K for the second quarter 2026 (Q2 2026), +2% from a year earlier and +14% from the quarter before.
Source: Co-Diagnostics 10-Q on SEC EDGAR.